Dianthus Therapeutics (NASDAQ:DNTH) Trading Down 8.1% – Should You Sell?

Dianthus Therapeutics, Inc. (NASDAQ:DNTH)’s share price fell 8.1% on Friday . The stock traded as low as $23.18 and last traded at $23.43. 54,709 shares traded hands during trading, a decline of 73% from the average session volume of 202,782 shares. The stock had previously closed at $25.49.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on DNTH. Baird R W raised Dianthus Therapeutics to a “strong-buy” rating in a report on Friday, July 26th. HC Wainwright reissued a “buy” rating and set a $40.00 price target on shares of Dianthus Therapeutics in a research report on Monday, November 11th. Wedbush dropped their price objective on shares of Dianthus Therapeutics from $38.00 to $36.00 and set an “outperform” rating on the stock in a report on Friday, August 9th. Robert W. Baird assumed coverage on shares of Dianthus Therapeutics in a report on Friday, July 26th. They set an “outperform” rating and a $58.00 target price for the company. Finally, Raymond James boosted their target price on shares of Dianthus Therapeutics from $51.00 to $56.00 and gave the company an “outperform” rating in a research report on Friday, November 8th. Eight analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $46.43.

Dianthus Therapeutics Stock Down 8.4 %

The company’s 50-day moving average is $27.58 and its 200 day moving average is $26.68. The company has a market cap of $691.46 million, a price-to-earnings ratio of -9.34 and a beta of 1.84.

Dianthus Therapeutics (NASDAQ:DNTH) last posted its earnings results on Thursday, November 7th. The company reported ($0.74) EPS for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.15). The business had revenue of $2.17 million for the quarter, compared to analyst estimates of $1.07 million. Dianthus Therapeutics had a negative net margin of 1,250.32% and a negative return on equity of 21.68%. Analysts predict that Dianthus Therapeutics, Inc. will post -2.61 EPS for the current fiscal year.

Institutional Trading of Dianthus Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Barclays PLC lifted its position in shares of Dianthus Therapeutics by 390.5% during the 3rd quarter. Barclays PLC now owns 41,684 shares of the company’s stock valued at $1,141,000 after buying an additional 33,185 shares in the last quarter. Jane Street Group LLC acquired a new position in Dianthus Therapeutics during the third quarter worth $556,000. Wellington Management Group LLP purchased a new position in Dianthus Therapeutics during the third quarter valued at $1,473,000. State Street Corp grew its position in shares of Dianthus Therapeutics by 101.4% in the third quarter. State Street Corp now owns 821,131 shares of the company’s stock valued at $22,483,000 after purchasing an additional 413,425 shares during the period. Finally, Point72 Asset Management L.P. raised its position in shares of Dianthus Therapeutics by 151.3% during the 3rd quarter. Point72 Asset Management L.P. now owns 437,700 shares of the company’s stock worth $11,984,000 after purchasing an additional 263,500 shares during the last quarter. 47.53% of the stock is currently owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy.